Royalty Pharma (RPRX) Earnings Expected to Grow: Should You Buy?
Royalty Pharma (RPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
| Ticker |
ACIU
|
| CIK | 0001651625 |
| SIC | 2834 |
| Sector | Manufacturing |
| Industry Category | Pharmaceutical Products |
| Industry Group | Pharmaceutical Preparations |
| Address | EPFL INNOVATION PARK, BUILDING B, 1015 LAUSANNE, V8, 00000 |
| Website | acimmune.com |
| Phone | 41 21 345 91 21 |
| CEO | Andrea Pfeifer |
| Employees | 140 |
Our team will help you customize a package that meets the needs of your business.
Request a Consultation|
Standardized FinancialsdocsIntrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals. For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards. Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics: |
|||||||||||||||||||||
|
Income Statement
|
Balance Sheet
|
||||||||||||||||||||
|
Cash Flow Statement
|
Calculations
|
||||||||||||||||||||
|
Latest NewsdocsIntrinio provides up-to-date news articles on every US company from various sources. Here are several examples: |
Royalty Pharma (RPRX) Earnings Expected to Grow: Should You Buy?Royalty Pharma (RPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. AC Immune (ACIU) May Report Negative Earnings: Know the Trend Ahead of Q2 ReleaseAC Immune (ACIU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. Discovering Opportunities: 3 Penny Stocks With Market Caps Over $200MThe United States market has shown positive momentum, rising 1.3% in the last week and 15% over the past year, with earnings expected to grow annually by 15%. While the term 'penny stock' may seem outdated, it still signifies opportunities within smaller or newer companies that can offer significant returns when supported by strong financials. In this article, we explore three penny stocks that stand out for their balance sheet strength and potential for growth, offering investors a chance to... June 2025 Penny Stocks With Promising PotentialThe market has climbed 1.6% in the last 7 days and is up 12% over the last 12 months, with earnings forecast to grow by 14% annually. In such a robust environment, identifying stocks with strong financial fundamentals is crucial for investors seeking growth potential. Although 'penny stocks' might seem like an outdated term, these smaller or newer companies can offer compelling opportunities when they demonstrate balance sheet resilience and financial strength. AC Immune (ACIU) Reports Q1 Loss, Lags Revenue EstimatesAC Immune (ACIU) delivered earnings and revenue surprises of 4.55% and 3.42%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock? |